Obesity Medicine

 
Smoking Rates Hit New Low, But Cervical Cancer Screening Still Lags: 2025 ACS Report
April 24, 2025

While smoking in the US continues to decline, the American Cancer Society reports mixed progress in major cancer risk factors, prevention, and screening.

Lilly’s Oral GLP-1 Orforglipron Shows Significant and Competitive A1c and Weight Reductions in Phase 3 Trial
April 17, 2025

The positive topline data from the phase 3 ACHIEVE-1 trial suggest the small molecule GLP-1 mimetic could compete with blockbuster weekly injectables for reducing weight, A1c.

A Comprehensive Approach to Obesity Treatment: Combining Lifestyle, Medication, and Surgery
April 16, 2025

ACP 2025: GLP-1 medications are advancing obesity care, but lifestyle changes and bariatric surgery remain key components. Laura Davisson, MD, discusses how to personalize treatment strategies.

Mediterranean Diet Combined with Physical Activity Mitigate Bone Density Decline in Older, At-Risk Women, New Analysis Finds
April 15, 2025

Following a Mediterranean-style diet and a prescribed regimen of physical activity was significantly protective of BMD, particularly at the lumbar level, over 3 years.

FDA, Novo Nordisk Investigating Counterfeit Semaglutide Injection in US Supply Chain
April 14, 2025

The FDA and Novo Nordisk are urging health care professionals to check semaglutide (Ozempic) injection 1 mg lot PAR0362 with serials starting 51746517.

Tirzepatide Improves Heart Failure Symptoms and Renal Function in People with Obesity, CKD
April 11, 2025

ACC 2025. Tirzepatide improved HF symptoms and renal function in patients with obesity-related HFpEF, regardless of CKD status, according to new findings from the SUMMIT trial.

Incretin-Based Obesity Medications Show Minimal Lean Muscle Mass Loss in 6-Month Prospective Study
April 10, 2025

Loss of lean muscle mass along with fat mass is a concerning side effect of the incretin-based antiobesity medications, making the new study results encouraging.

Navigating GLP-1 Medication Access: Coverage Challenges, Emerging Cash-Pay Options
April 08, 2025

ACP 2025: Laura Davisson, MD, outlines how PCPs can navigate GLP-1 medication coverage issues and why to consider recent cash-pay options.

Switching to Tirzepatide Outweighs Escalating Dulaglutide Dose in T2D: SURPASS-SWITCH Trial
April 04, 2025

Breaking research presented at ACP Internal Medicine 2025 showed that switching GLP1-RAs resulted in better glucose and weight control among adults with inadequately controlled T2D.

Responsive Parenting Intervention Curbs Childhood Obesity Risk: Daily Dose
April 03, 2025

Your daily dose of the clinical news you may have missed.